A Systems Biology approach to cancer is challenging because it requires a truly integrated team approach — including cancer biologists with a deep understanding of the biological and clinical aspects of the disease; genomic scientists with the ability to generate large-scale data in an accurate and efficient manner; and computational scientists with the ability to create predictive models from rich datasets. We believe this is best done by having excellent scientists come together as part of a single project team to take on a common large challenge (rather than to employ a loosely knit program project model). Our Center brings together a group of 11 experienced investigators from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard (which includes the former Whitehead/MIT Center for Genome Research).
Todd Golub, M.D., Director of the Cancer Program at the Broad Institute and the Charles A. Dana Investigator at the Dana-Farber Cancer Institute, Associate Professor of Pediatrics at Harvard Medical School, and Associate Investigator of the Howard Hughes Medical Institute.
Jill Mesirov, Ph.D. is Chief Informatics Officer and Director of Computational Biology and Bioinformatics at the Broad Institute, and adjunct professor of bioinformatics at Boston University.
William Hahn, M.D., Ph.D. is Assistant Professor of Medicine at Harvard Medical School, investigator at the Dana-Farber Cancer Institute, and an Associate Member of the Cancer Program at the Broad Institute.
Eric Lander, Ph.D. is Director of the Broad Institute, a Member of the Whitehead Institute for Biomedical Research, and Professor of Biology at both MIT and Harvard.
Matthew Meyerson, M.D., Ph.D. is Assistant Professor of Pathology at Harvard Medical School, Investigator at the Dana-Farber Cancer Institute, and Associate Member of the Cancer Program at the Broad Institute.
Thomas Roberts, Ph.D. is Professor of Pathology and Chairman of the Division of Medical Sciences at Harvard Medical School, and is co-chairman of the Department of Cancer Biology at the Dana-Farber Cancer Institute.
James Griffin, M.D. is Professor of Medicine at Harvard Medical School and Chairman of the Department of Adult Oncology at the Dana-Farber Cancer Institute.
Ed Harlow, Ph.D. is Professor and Chair of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, a leader of the Harvard Institute of Proteomics, and Associate Member of the Broad Institute.
D. Gary Gilliland, M.D., Ph.D. is Professor of Medicine at Harvard Medical School and an Investigator of the Howard Hughes Medical Institute.
Pablo Tamayo, Ph.D. is the lead computational biologist in the Cancer Program at the Broad Institute.
Steven Carr, Ph.D., Director of Proteomics at the Broad Institute.
In addition, the Center benefits from the work of a committed group of inter-disciplinary scientists, including:
- Justin Lamb, Ph.D. (chemical genomics)
- Haley Hieronymus, Ph.D. (kinase signature development)
- Jinyan Du, Ph.D. (proteomics)
- Carl Klauser, Ph.D. (proteomics)
- David Root, Ph.D. (RNA interference)
- Gad Getz, Ph.D. (computational biology)
- David Peck (gene expression profiling)
- Michael Reich (kinase signature database development)